JP2008507477A - ポリペプチド延長タグ - Google Patents

ポリペプチド延長タグ Download PDF

Info

Publication number
JP2008507477A
JP2008507477A JP2007519766A JP2007519766A JP2008507477A JP 2008507477 A JP2008507477 A JP 2008507477A JP 2007519766 A JP2007519766 A JP 2007519766A JP 2007519766 A JP2007519766 A JP 2007519766A JP 2008507477 A JP2008507477 A JP 2008507477A
Authority
JP
Japan
Prior art keywords
glp
xaa
ethoxy
peptide
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007519766A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008507477A5 (enExample
Inventor
ドールワルド、フロレンシオ・ザラゴザ
シオドト、クリスティン・ブルーン
ハンセン、トーマス・クルセ
マドセン、クジェルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2008507477A publication Critical patent/JP2008507477A/ja
Publication of JP2008507477A5 publication Critical patent/JP2008507477A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
JP2007519766A 2004-07-08 2005-06-21 ポリペプチド延長タグ Pending JP2008507477A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200401083 2004-07-08
EP05102167 2005-03-18
PCT/EP2005/052874 WO2006005667A2 (en) 2004-07-08 2005-06-21 Polypeptide protracting tags comprising a tetrazole moiety

Publications (2)

Publication Number Publication Date
JP2008507477A true JP2008507477A (ja) 2008-03-13
JP2008507477A5 JP2008507477A5 (enExample) 2012-05-24

Family

ID=35453538

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007519766A Pending JP2008507477A (ja) 2004-07-08 2005-06-21 ポリペプチド延長タグ

Country Status (12)

Country Link
US (2) US20090111730A1 (enExample)
EP (3) EP2289560B1 (enExample)
JP (1) JP2008507477A (enExample)
KR (1) KR20070029247A (enExample)
CN (1) CN101005857A (enExample)
AU (1) AU2005261740A1 (enExample)
BR (1) BRPI0512988A (enExample)
CA (1) CA2572770A1 (enExample)
ES (2) ES2564167T3 (enExample)
MX (1) MXPA06015049A (enExample)
RU (1) RU2006144821A (enExample)
WO (1) WO2006005667A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520847A (ja) * 2008-05-16 2011-07-21 ノボ・ノルデイスク・エー／エス 遅効型ｙ２及び／又はｙ４レセプターアゴニスト
JP2012515747A (ja) * 2009-01-23 2012-07-12 ノヴォ・ノルディスク・アー／エス アルブミンバインダーａ−ｂ−ｃ−ｄ−ｅ−を有するｆｇｆ２１誘導体及びそれらの使用
JP2013532644A (ja) * 2010-07-20 2013-08-19 ノヴォ ノルディスク アー／エス Ｎ末端が修飾されたｆｇｆ２１化合物
KR20170095256A (ko) * 2014-12-23 2017-08-22 노보 노르디스크 에이/에스 Fgf21 유도체 및 그것의 용도

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007011307A (es) * 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
JP5252435B2 (ja) * 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
WO2008023050A1 (en) * 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
US20100016237A1 (en) * 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
EP2106406A2 (en) * 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
WO2008087189A2 (en) * 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP2101822A2 (en) * 2007-01-18 2009-09-23 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
JP2010517943A (ja) * 2007-01-18 2010-05-27 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
WO2009030738A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
ES2550363T3 (es) * 2007-09-05 2015-11-06 Novo Nordisk A/S Derivados truncados de GLP-1 y su uso terapéutico
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US8486892B2 (en) 2008-01-23 2013-07-16 Novo Nordisk Health Care Ag Blood coagulation factor inhibitors
DK2254906T3 (en) 2008-03-18 2017-01-23 Novo Nordisk As Protease-stabilized acylated insulin analogues
WO2009141392A1 (en) * 2008-05-22 2009-11-26 Novo Nordisk A/S Process
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
WO2010046357A1 (en) 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives
AU2009334289A1 (en) * 2008-12-29 2011-07-28 Panacea Biotec Ltd GLP-1 analogs and uses thereof
CN102292349B (zh) 2009-01-22 2016-04-13 诺沃—诺迪斯克保健股份有限公司 稳定的生长激素化合物
CN102612376A (zh) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
JP2013505221A (ja) * 2009-09-18 2013-02-14 ノヴォ ノルディスク アー／エス 長時間作用性ｙ２受容体アゴニスト
WO2011058165A1 (en) * 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
MX345736B (es) 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Hormonas de crecimiento con eficacia in vivo prolongada.
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
EP2560675A1 (en) 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
KR101922164B1 (ko) 2011-12-29 2019-02-13 노보 노르디스크 에이/에스 비-단백질원 아미노산을 포함하는 디펩티드
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
JP2016500682A (ja) 2012-10-17 2016-01-14 ノヴォ ノルディスク アー／エス 経口ペプチドデリバリーのための脂肪酸アシル化アミノ酸
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
CN103304499B (zh) * 2013-06-02 2015-03-04 张远强 抗糖尿病化合物、其制备方法和用途
CN103304501B (zh) * 2013-06-02 2015-03-04 张远强 一类抗糖尿病化合物、其制备方法和用途
CN103304503B (zh) * 2013-06-02 2015-03-04 张远强 抗糖尿病化合物、其制备方法和用途
CN103304502B (zh) * 2013-06-02 2015-03-04 张远强 一类抗糖尿病化合物、其制备方法和用途
PL3013796T3 (pl) * 2013-06-27 2020-06-15 Lg Chem, Ltd. Pochodne biarylowe jako agoniści gpr120
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
US9085637B2 (en) 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
TWI694082B (zh) 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
CN107589246B (zh) * 2017-03-07 2019-10-01 上海原科实业发展有限公司 一种纤维蛋白激活剂、其制备方法，包括该激活剂的试剂盒及采用该试剂盒的检测方法
JP2020527159A (ja) 2017-07-19 2020-09-03 ノヴォ ノルディスク アー／エス Ｅｇｆ（ａ）類似体、その製造、製剤および使用
US12304932B2 (en) 2017-11-14 2025-05-20 Senju Pharmaceutical Co., Ltd. PACAP stabilized peptide
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
WO2019193204A1 (en) 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2019229242A1 (en) 2018-05-31 2019-12-05 Novo Nordisk A/S Derivatives comprising an apelin analogue and uses thereof
CA3122636A1 (en) 2018-12-11 2020-06-18 Sanofi Insulin analogs having reduced insulin receptor binding affinity
US20240239859A1 (en) * 2019-12-30 2024-07-18 Gan & Lee Pharmaceuticals Co., Ltd. Long-Acting GLP-1 Compound
CN111333714A (zh) * 2020-03-05 2020-06-26 成都奥达生物科技有限公司 一种长效glp-1化合物
JP7777085B2 (ja) 2020-04-29 2025-11-27 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
EP4210680A1 (en) 2020-09-07 2023-07-19 Cyprumed GmbH Improved pharmaceutical formulations of glp-1 receptor agonists
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
EP4642440A1 (en) 2022-12-30 2025-11-05 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2024179606A1 (zh) * 2023-03-02 2024-09-06 甘李药业股份有限公司 一种glp-1化合物的医药用途
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522482A (ja) * 1998-08-14 2002-07-23 ジー・ピー・アイ ニイル ホールディングス インコーポレィティッド 視力及び記憶障害に対する多様な異種原子を有するヘテロサイクリック環化合物のカルボン酸及び同配体
WO2002058690A2 (en) * 2001-01-26 2002-08-01 Chugai Seiyaku Kabushiki Kaisha Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
WO2002066035A2 (en) * 2001-02-20 2002-08-29 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
US6492531B1 (en) * 1992-02-18 2002-12-10 Warner-Lambert Company Method of treating cognitive disorders
WO2003000180A2 (en) * 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2003013573A1 (en) * 2001-08-10 2003-02-20 Epix Medical, Inc. Polypeptide conjugates with extended circulating half-lives
WO2003045371A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
WO2003061567A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
WO2003062248A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
WO2003082861A2 (en) * 2002-03-28 2003-10-09 Glaxo Group Limited Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
WO2003099805A1 (en) * 2002-05-28 2003-12-04 3-Dimensional Pharmaceuticals, Inc. Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
WO2003103653A1 (en) * 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
WO2004050653A2 (en) * 2002-12-03 2004-06-17 Ciba Specialty Chemicals Holding Inc. Oxime ester photoinitiators with heteroaromatic groups
JP2006509790A (ja) * 2002-11-27 2006-03-23 アルテシアン セラピューティック，インコーポレイティド 心不全の治療のための混合されたＰＤＥ阻害およびβアドレナリン拮抗薬活性または部分的作用薬活性を有する化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869437A (en) * 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US4423224A (en) * 1980-09-08 1983-12-27 Sds Biotech Corporation 4-Me-1-(2-(1H-tetrazol-5-yl)ethyl)benzene sulfonate and N-2-(1H-tetrazol-5-yl)ethyl methanesulfonamide
JPS604165A (ja) * 1983-06-21 1985-01-10 Taiho Yakuhin Kogyo Kk スルホニウム誘導体
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3626130A1 (de) * 1986-08-01 1988-02-11 Merck Patent Gmbh Aminosaeurederivate
WO1992001476A1 (en) 1990-07-26 1992-02-06 University Of Iowa Research Foundation Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
TW289757B (enExample) * 1993-05-08 1996-11-01 Hoechst Ag
US5776927A (en) * 1994-04-18 1998-07-07 Corvas International, Inc. Methionine sulfone and S-substituted cysteine sulfone derivatives as enzyme inhibitors
US5883107A (en) * 1994-06-17 1999-03-16 Corvas International, Inc. Arginine mimic derivatives as enzyme inhibitors
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
DE19521653A1 (de) * 1995-06-14 1996-12-19 Hoechst Schering Agrevo Gmbh Substituierte Tetrazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und Pflanzenwachstumsregulatoren
JPH09136878A (ja) 1995-09-12 1997-05-27 Ono Pharmaceut Co Ltd テトラゾール誘導体
EP0761680A3 (en) * 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
WO1999058518A2 (en) 1998-05-12 1999-11-18 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6358705B1 (en) 1998-07-16 2002-03-19 Novo Nordisk A/S Method of making proteins in transformed yeast cells
DK1143989T3 (da) * 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendiner til glucagonundertrykkelse
WO2003027081A2 (en) * 2001-09-14 2003-04-03 Novo Nordisk A/S NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER
CN1671363A (zh) 2002-06-07 2005-09-21 兰贝克赛实验室有限公司 二丙戊酸钠的缓释制剂
DE60317565T2 (de) 2002-12-20 2008-09-11 Novo Nordisk A/S Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden
AU2004218808A1 (en) 2003-03-11 2004-09-23 Novo Nordisk A/S Pharmaceutical preparations comprising acid-stabilised insulin
TW200526254A (en) * 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
US20050096466A1 (en) * 2003-09-19 2005-05-05 Schwinden Mark D. Process for the preparation of tetrazol-derived compounds as growth hormone secretagogues
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CN101665538A (zh) * 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
JP4933455B2 (ja) * 2005-02-02 2012-05-16 ノヴォ ノルディスク アー／エス 新規のインスリン誘導体
WO2013041678A1 (en) * 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492531B1 (en) * 1992-02-18 2002-12-10 Warner-Lambert Company Method of treating cognitive disorders
JP2002522482A (ja) * 1998-08-14 2002-07-23 ジー・ピー・アイ ニイル ホールディングス インコーポレィティッド 視力及び記憶障害に対する多様な異種原子を有するヘテロサイクリック環化合物のカルボン酸及び同配体
JP2004521113A (ja) * 2001-01-26 2004-07-15 中外製薬株式会社 マロニル−ＣｏＡ脱炭酸酵素阻害剤を用いた疾患の治療法
WO2002058690A2 (en) * 2001-01-26 2002-08-01 Chugai Seiyaku Kabushiki Kaisha Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
WO2002066035A2 (en) * 2001-02-20 2002-08-29 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
JP2004522773A (ja) * 2001-02-20 2004-07-29 中外製薬株式会社 代謝調節剤として有用なマロニル−ＣｏＡ脱炭酸酵素阻害剤としてのアゾール
WO2003000180A2 (en) * 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
JP2004535433A (ja) * 2001-06-20 2004-11-25 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療用のジペプチジルペプチダーゼ阻害薬
WO2003013573A1 (en) * 2001-08-10 2003-02-20 Epix Medical, Inc. Polypeptide conjugates with extended circulating half-lives
WO2003045371A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
JP2005513030A (ja) * 2001-11-30 2005-05-12 ファイザー・プロダクツ・インク 医薬組成物及びｅｐ２受容体選択的アゴニストの投与方法
WO2003062248A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
WO2003061567A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
JP2005527494A (ja) * 2002-01-18 2005-09-15 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
WO2003082861A2 (en) * 2002-03-28 2003-10-09 Glaxo Group Limited Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
WO2003099805A1 (en) * 2002-05-28 2003-12-04 3-Dimensional Pharmaceuticals, Inc. Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
JP2005538953A (ja) * 2002-05-28 2005-12-22 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド 新規チオフェンアミジン、それらの組成物、および補体媒介疾患および病気を治療する方法
WO2003103653A1 (en) * 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
JP2006509790A (ja) * 2002-11-27 2006-03-23 アルテシアン セラピューティック，インコーポレイティド 心不全の治療のための混合されたＰＤＥ阻害およびβアドレナリン拮抗薬活性または部分的作用薬活性を有する化合物
WO2004050653A2 (en) * 2002-12-03 2004-06-17 Ciba Specialty Chemicals Holding Inc. Oxime ester photoinitiators with heteroaromatic groups

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012049299; ＫＮＵＤＳＥＮ，Ｌ．Ｂ．　ｅｔ　ａｌ: 'Ｐｏｔｅｎｔ　ｄｅｒｉｖａｔｉｖｅｓ　ｏｆ　ｇｌｕｃａｇｏｎ-ｌｉｋｅ　ｐｅｐｔｉｄｅ-１　ｗｉｔｈ　ｐｈａｒｍａｃｏｋｉｎｅｔｉｃ　ｐｒｏｐｅｒｔｉｅｓ　ｓｕｉｔａｂｌｅ　ｆｏｒ　ｏｎｃｅ　ｄａｉｌ' Ｊ　Ｍｅｄ　Ｃｈｅｍ Ｖｏｌ．４３，　Ｎｏ．９, 2000, ｐ．１６６４-９ *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520847A (ja) * 2008-05-16 2011-07-21 ノボ・ノルデイスク・エー／エス 遅効型ｙ２及び／又はｙ４レセプターアゴニスト
JP2012515747A (ja) * 2009-01-23 2012-07-12 ノヴォ・ノルディスク・アー／エス アルブミンバインダーａ−ｂ−ｃ−ｄ−ｅ−を有するｆｇｆ２１誘導体及びそれらの使用
US9480753B2 (en) 2009-01-23 2016-11-01 Novo Nordisk A/S FGF21 derivatives with albumin binder A-B-C-D-E- and their use
JP2013532644A (ja) * 2010-07-20 2013-08-19 ノヴォ ノルディスク アー／エス Ｎ末端が修飾されたｆｇｆ２１化合物
US9655974B2 (en) 2010-07-20 2017-05-23 Novo Nordisk A/S N-terminal modified FGF21 compounds
KR20170095256A (ko) * 2014-12-23 2017-08-22 노보 노르디스크 에이/에스 Fgf21 유도체 및 그것의 용도
US9744213B2 (en) 2014-12-23 2017-08-29 Novo Nordisk A/S FGF21 derivatives and uses thereof
US9895417B2 (en) 2014-12-23 2018-02-20 Novo Nordisk A/S FGF21 derivatives and uses thereof
US10124039B2 (en) 2014-12-23 2018-11-13 Novo Nordisk A/S FGF21 derivatives and uses thereof
KR102427527B1 (ko) 2014-12-23 2022-08-01 노보 노르디스크 에이/에스 Fgf21 유도체 및 그것의 용도

Also Published As

Publication number Publication date
RU2006144821A (ru) 2008-08-20
AU2005261740A1 (en) 2006-01-19
ES2542228T3 (es) 2015-08-03
CA2572770A1 (en) 2006-01-19
EP1765408B1 (en) 2015-12-09
WO2006005667A2 (en) 2006-01-19
EP2289560B1 (en) 2015-04-22
MXPA06015049A (es) 2007-02-08
CN101005857A (zh) 2007-07-25
EP2289560A3 (en) 2011-10-19
BRPI0512988A (pt) 2008-04-22
US9061067B2 (en) 2015-06-23
EP2292272A2 (en) 2011-03-09
EP2292272A3 (en) 2011-10-26
US20090111730A1 (en) 2009-04-30
WO2006005667A3 (en) 2006-10-12
US20120088716A1 (en) 2012-04-12
KR20070029247A (ko) 2007-03-13
ES2564167T3 (es) 2016-03-18
EP2289560A2 (en) 2011-03-02
EP1765408A2 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
US9061067B2 (en) Polypeptide protracting tags
US7897560B2 (en) Plasma protein affinity tags
JP4585037B2 (ja) アシル化ｇｌｐ−１化合物
ES2532116T3 (es) Péptidos derivados con A-B-C-D y sus usos terapéuticos
JP5476304B2 (ja) グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
JP5755398B2 (ja) 伸長されたｇｌｐ−１化合物
KR101241862B1 (ko) 신규 ｇｌｐ-1 유도체
CN103200966B (zh) 具有接头的双-酰化的glp-1衍生物
JP2007537141A (ja) 新規なｇｌｐ−１化合物
JP2008533104A (ja) Ｇｌｐ−１受容体の二量体ペプチドアゴニスト
JP2008530178A (ja) 構造的に明確に定義された分枝重合体と抱合されたインスリン分泌性薬剤の誘導体
JP2008516621A (ja) 成長ホルモン結合体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111202

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120330

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131001